In vitro comparison of dibekacin and gentamicin activities

Hill, C D; Counts, George W.; Turck, Marvin

doi:10.1128/aac.19.1.190

Antimicrob Agents Chemother

1981

DOI: 10.1128/aac.19.1.190

|View full text |Cite

In vitro comparison of dibekacin and gentamicin activities

C D Hill¹,

George W. Counts²,

Marvin Turck³

Abstract: Dibekacin, a new parenteral aminoglycoside, was compared with gentamicin in vitro against 221 clinical isolates. Tests for minimum inhibitory concentrations, performed in agar, demonstrated that dibekacin was comparable to gentamicin against most isolates tested. Dibekacin was slightly more active than gentamicin against some isolates of Pseudomonas aeruginosa, but was significantly less active against strains of Serratia.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1984

2022

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

In vitro comparison of aminoglycoside activities and their synergistic action with piperacillin

Hoogkamp-Korstanje¹

1985

Infection

View full text Add to dashboard Cite

The antimicrobial activity of six aminoglycosides against 927 clinical isolates was compared. Gentamicin and netilmicin were most active against Enterobacteriaceae, followed by tobramycin greater than dibekacin greater than amikacin greater than kanamycin. Tobramycin was most active against Pseudomonas aeruginosa, both mucoid and non-mucoid strains, followed by dibekacin greater than gentamicin greater than netilmicin greater than amikacin greater than kanamycin. Piperacillin-aminoglycoside combinations acted (partially) synergistically against 33-40% of the Enterobacteriaceae, 34-58% of non-mucoid strains of P. aeruginosa and 63-84% of the mucoid strains of P. aeruginosa (p less than 0.01). Piperacillin + gentamicin was the most synergistic combination against Enterobacteriaceae and non-mucoid strains of P. aeruginosa (p less than 0.05). The action against Staphylococcus aureus and Streptococcus faecalis was mostly indifferent. Antagonism was not observed. In treating gram-negative infections where tissue concentrations are less important, every aminoglycoside combination may be effective; for Pseudomonas lung infections in cystic fibrosis, piperacillin + gentamicin or tobramycin will remain the drugs of first choice.

show abstract

In vitro comparison of aminoglycoside activities and their synergistic action with piperacillin

Hoogkamp-Korstanje¹

1985

Infection

View full text Add to dashboard Cite

show abstract

Sisomicin, Netilmicin and Dibekacin

Noone

1984

Drugs

View full text Add to dashboard Cite

Sisomicin is a naturally occurring aminoglycoside antibiotic produced by Micromonospora inyoensis, while dibekacin and netilmicin are both semisynthetic aminoglycosides. Dibekacin is 3',4'-dideoxykanamycin B and netilmicin is 1-N-ethyl sisomicin. In both cases, these modifications render the agents insusceptible to some of the enzymes found in resistant strains of bacteria which inactivate the parent compounds. Antibacterial activity: All 3 drugs show bactericidal activity against a wide range of Gram-negative bacteria (including E. coli, Enterobacter, Klebsiella and Proteus spp. and Ps. aeruginosa) and also against staphylococci; however, in common with other amino-glycosides, streptococci are usually resistant (except when beta-lactam antibiotics are used in combination) and anaerobic organisms are not sensitive. Sisomicin is closely related structurally to gentamicin Cla, but in vitro studies have shown it to have superior activity to gentamicin against Ps. aeruginosa, closely paralleling the activity of tobramycin, while still possessing the high activity of gentamicin against Serratia and other Gram-negative rods. However, sisomicin is inactivated by virtually all bacterial enzymes which inactivate gentamicin and tobramycin. Nevertheless, it retains useful activity against a number of gentamicin-resistant strains of Ps. aeruginosa which are resistant by non-enzymatic (possibly permeability barrier) mechanisms; in this respect it closely resembles tobramycin. Dibekacin closely resembles tobramycin structurally and in vitro it seems to have a very similar antibacterial spectrum, including activity against some strains of Ps. aeruginosa resistant to gentamicin. Netilmicin has a generally broader antibacterial spectrum than gentamicin, tobramycin, sisomicin or debekacin and is resistant to inactivation by phosphorylating and adenylylating enzymes; however, it is inactivated by all acetylases, apart from acetylase 3-I. Its spectrum is therefore not as wide as that of amikacin against 'gentamicin-resistant' strains. Nonetheless, it is intrinsically more active than amikacin, weight-for-weight, against sensitive strains, apart possibly from Ps. aeruginosa. In fact, its activity against species of the Enterobacteriaceae and staphylococci sensitive to gentamicin is of the same order as the latter and possibly better for Klebsiella-Enterobacter species. All 3 agents show marked antibacterial synergy with a variety of beta-lactam antibiotics against a range of bacteria. Pharmacokinetically, sisomicin, netilmicin and dibekacin all behave like gentamicin. All 3 drugs are excreted in the urine unchanged and have beta-phase elimination half-lives of around 2 to

show abstract

Discovery and Development of Antibacterial Agents: Fortuitous and Designed

Kaur

Rani

Atanasov

et al. 2022

MRMC

View full text Add to dashboard Cite

Today, antibacterial drug resistance has turned into a significant public health issue. Repeated intake, suboptimal and/or unnecessary use of antibiotics, and, additionally, the transfer of resistance genes are the critical elements that make microorganisms resistant to conventional antibiotics. A substantial number of antibacterials that were successfully utilized earlier for prophylaxis and therapeutic purposes have been rendered inadequate due to this phenomenon. Therefore, the exploration of new molecules has become a continuous endeavour. Many such molecules are at various stages of investigation. A surprisingly high number of new molecules are currently in the stage of phase 3 clinical trials. A few new agents have been commercialized in the last decade. These include solithromycin, plazomicin, lefamulin, omadacycline, eravacycline, delafloxacin, zabofloxacin, finafloxacin, nemonoxacin, gepotidacin, zoliflodacin, cefiderocol, BAL30072, avycaz, zerbaxa, vabomere, relebactam, tedizolid, cadazolid, sutezolid, triclosan and afabiacin. This article aims to review the investigational and recently approved antibacterials with a focus on their structure, mechanisms of action/resistance, and spectrum of activity. Delving deep, their success or otherwise in various phases of clinical trials is also discussed while attributing the same to various causal factors.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

In vitro comparison of dibekacin and gentamicin activities

Cited by 3 publications

References 3 publications

In vitro comparison of aminoglycoside activities and their synergistic action with piperacillin

In vitro comparison of aminoglycoside activities and their synergistic action with piperacillin

Sisomicin, Netilmicin and Dibekacin

Discovery and Development of Antibacterial Agents: Fortuitous and Designed

Contact Info

Product

Resources

About